- Home
- HOOK vs WATT Comparison
HOOK vs WATT Comparison
Compare HOOK & WATT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- WATT
- Stock Information
- Founded
- HOOK 2011
- WATT 2012
- Country
- HOOK United States
- WATT United States
- Employees
- HOOK N/A
- WATT N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- WATT Radio And Television Broadcasting And Communications Equipment
- Sector
- HOOK Health Care
- WATT Technology
- Exchange
- HOOK Nasdaq
- WATT Nasdaq
- Market Cap
- HOOK 9.3M
- WATT 9.9M
- IPO Year
- HOOK 2019
- WATT 2014
- Fundamental
- Price
- HOOK $1.25
- WATT $0.28
- Analyst Decision
- HOOK Buy
- WATT
- Analyst Count
- HOOK 4
- WATT 0
- Target Price
- HOOK $10.67
- WATT N/A
- AVG Volume (30 Days)
- HOOK 62.9K
- WATT 569.9K
- Earning Date
- HOOK 08-07-2025
- WATT 08-07-2025
- Dividend Yield
- HOOK N/A
- WATT N/A
- EPS Growth
- HOOK N/A
- WATT N/A
- EPS
- HOOK N/A
- WATT N/A
- Revenue
- HOOK $9,351,000.00
- WATT $1,047,000.00
- Revenue This Year
- HOOK N/A
- WATT $1,028.91
- Revenue Next Year
- HOOK N/A
- WATT N/A
- P/E Ratio
- HOOK N/A
- WATT N/A
- Revenue Growth
- HOOK N/A
- WATT 137.41
- 52 Week Low
- HOOK $0.72
- WATT $0.12
- 52 Week High
- HOOK $6.77
- WATT $2.70
- Technical
- Relative Strength Index (RSI)
- HOOK 38.94
- WATT 52.37
- Support Level
- HOOK $1.23
- WATT $0.25
- Resistance Level
- HOOK $1.30
- WATT $0.29
- Average True Range (ATR)
- HOOK 0.06
- WATT 0.02
- MACD
- HOOK -0.03
- WATT 0.00
- Stochastic Oscillator
- HOOK 5.97
- WATT 60.00
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs, and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. The WPN technology provides a comprehensive suite of capabilities designed to power the next generation of wireless energy networks, seamlessly delivering power and data across diverse, battery-free device ecosystems. It enhances operational visibility, control, and intelligent business automation. Its products include Transmitter IC & Module, Receivers IC, Transmitter System, and Evaluation Kits.